Celltrion posted record high quarterly sales for the second consecutive quarter, with balanced growth in core and new biosimilar products. Operating profit improved by a massive 371% sequentially.
What is covered in the Full Insight:
Q2 24 Financial Performance
Biosimilars on High Trajectory
Operating Profit Improvement Outlook
Approval of New Biosimilar Products
Conclusion and Outlook
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.